Advancing Personalized Treatment of Alzheimer's Disease: A Call for the N-of-1 Trial Design

References

• Lillie EO , PatayB, DiamantJet al. The n-of-1 clinical trial: the ultimate strategy for individualizing medicine? Per. Med. 8, 161–173 (2011).
   PubMed Web of Science ®Google Scholar
• Davidson KW , PeacockJ, KronishIM, EdmondsonD. Personalizing behavioral interventions through single-patient (N-of-1) trials. Soc. Personal Psychol. Compass.8, 408–421 (2014).
   PubMedGoogle Scholar
• Demeyin WA , FrostJ, UkoumunneOC, BriscoeS, BrittenN. N of 1 trials and the optimal individualisation of drug treatments: a systematic review protocol. Syst Rev.6, 90 (2017).
   PubMedGoogle Scholar
• Van Ness PH , MurphyTE, AliA. Attention to individuals: mixed methods for N-of-1 health care interventions. J. Mix. Methods Res.11, 342–354 (2017).
   PubMed Web of Science ®Google Scholar
• Vohra S . N-of-1 trials to enhance patient outcomes: identifying effective therapies and reducing harms, one patient at a time. J. Clin. Epidemiol.76, 6–8 (2016).
   PubMed Web of Science ®Google Scholar
• Ho D , ZarrinparA. Making N-of-1 medicine a reality. SLAS technol. 22, 231–232 (2017).
   Google Scholar
• Chen X , ChenP. A comparison of four methods for the analysis of N-of-1 trials. PLoS One9, e87752 (2014).
   PubMed Web of Science ®Google Scholar
• Sugeir S , NaylorS. Critical care and personalized or precision medicine: who needs whom?J. Crit. Care.43, 401–405 (2018).
   PubMed Web of Science ®Google Scholar
• Brannon EE , CushingCC, WaltersRW, CrickC, NoserAE, MullinsLL. Goal feedback from whom? A physical activity intervention using an N-of-1 RCT. Psychol. Health.9, 1–12 (2017).
   Google Scholar
• Abrahamyan L , FeldmanBM, TomlinsonGet al. Alternative designs for clinical trials in rare diseases. Am. J. Med. Genet. C. Semin. Med. Genet.172, 313–331 (2016).
   PubMed Web of Science ®Google Scholar
• Mirza RD , PunjaS, VohraS, GuyattG. The history and development of N-of-1 trials. J. R. Soc. Med.110, 330–340 (2017).
   PubMed Web of Science ®Google Scholar
• Guyatt GH , KellerJL, JaeschkeRet al. The n-of-1 randomized controlled trial: clinical usefulness. Our three-year experience. Ann. Intern. Med.112, 293–299 (1990).
   PubMed Web of Science ®Google Scholar
• Duan N , KravitzRL, SchmidCH. Single-patient (n-of-1) trials: a pragmatic clinical decision methodology for patient-centered comparative effectiveness research. J. Clin. Epidemiol.66(Suppl), S21–28 (2013).
   PubMedGoogle Scholar
• Cushing CC , WaltersRW, HoffmanL. Aggregated N-of-1 randomized controlled trials: modern data analytics applied to a clinically valid method of intervention effectiveness. J. Pediatr. Psychol.39, 138–150 (2014).
   PubMed Web of Science ®Google Scholar
• Clough AJ , HilmerSN, NaismithSL, KardellLD, GnjidicD. N-of-1 trials for assessing the effects of de-prescribing medications on short-term clinical outcomes in older adults: a systematic review. J. Clin. Epidemiol.93, 112–119 (2018).
   PubMed Web of Science ®Google Scholar
• Araujo A , JuliousS, SennS. Understanding variation in sets of N-of-1 trials. PLoS One.11, e0167167 (2016).
   PubMed Web of Science ®Google Scholar
• Punja S , BukutuC, ShamseerLet al. N-of-1 trials are a tapestry of heterogeneity. J. Clin. Epidemiol.76, 47–56 (2016).
   PubMed Web of Science ®Google Scholar
• McDonald S , QuinnF, VieiraRet al. The state of the art and future opportunities for using longitudinal n-of-1 methods in health behaviour research: a systematic literature overview. Health Psychol. Rev.11, 307–323 (2017).
   PubMed Web of Science ®Google Scholar
• Li J , WeiD, NiuJet al. Potential facilitators and barriers to awareness of N-of-1 trials for physicians in traditional Chinese medicine. Altern. Ther. Health Med. Oct 2. Pii, AT5470 (2017) ( Epub ahead of print).
   Web of Science ®Google Scholar
• Xie T , YuZ. N-of-1 Design and its applications to personalized treatment studies. Stat. Biosci.9, 662–675 (2017).
   PubMedGoogle Scholar
• Samuel JP , BellCS. Unique study designs in nephrology: N-of-1 trials and other designs. Adv. Chronic Kidney Dis.23, 351–354 (2016).
   PubMed Web of Science ®Google Scholar
• Gursli S , SandvikL, BakkeheimE, SkredeB, StugeB. Evaluation of a novel technique in airway clearance therapy – Specific Cough Technique (SCT) in cystic fibrosis: a pilot study of a series of N-of-1 randomised controlled trials. SAGE Open Med.5, 2050312117697505 (2017).
   PubMedGoogle Scholar
• Punja S , XuD, SchmidCHet al. N-of-1 trials can be aggregated to generate group mean treatment effects: a systematic review and meta-analysis. J. Clin. Epidemiol.76, 65–75 (2016).
   PubMed Web of Science ®Google Scholar
• Guyatt G . N of 1 randomized trials: a commentary. J. Clin. Epidemiol.76, 4–5 (2016).
   PubMed Web of Science ®Google Scholar
• Vohra S , ShamseerL, SampsonMet al. CENT Group . CONSORT extension for reporting N-of-1 trials (CENT) 2015 statement. J. Clin. Epidemiol.76, 9–17 (2016).
   PubMed Web of Science ®Google Scholar
• Porcino AJ , PunjaS, ChanAWet al. Protocol for a systematic review of N-of-1 trial protocol guidelines and protocol reporting guidelines. Syst. Rev.6, 132 (2017).
   PubMed Web of Science ®Google Scholar
• Shamseer L , SampsonM, BukutuCet al. CENT group . CONSORT extension for reporting N-of-1 trials (CENT) 2015: explanation and elaboration. J. Clin. Epidemiol.76, 18–46 (2016).
   PubMed Web of Science ®Google Scholar
• Senn S . Sample size considerations for n-of-1 trials. Stat. Methods Med. Res. doi:10.1177/0962280217726801 (2017) ( Epub ahead of print).
   PubMed Web of Science ®Google Scholar
• Herrett E , WilliamsonE, BeaumontDet al. Study protocol for statin web-based investigation of side effects (StatinWISE): a series of randomised controlled N-of-1 trials comparing atorvastatin and placebo in UK primary care. BMJ Open.7(12), e016604 (2017).
   PubMed Web of Science ®Google Scholar
• Vieira R , McDonaldS, Araújo-SoaresV, SniehottaFF, HendersonR. Dynamic modelling of n-of-1 data: powerful and flexible data analytics applied to individualised studies. Health Psychol. Rev.11, 222–234 (2017).
   PubMed Web of Science ®Google Scholar
• Jansen IH , Olde RikkertMG, HulsbosHA, HoefnagelsWH. Toward individualized evidence-based medicine: five “N of 1” trials of methylphenidate in geriatric patients. J. Am. Geriatr. Soc.49, 474–476 (2001).
   PubMed Web of Science ®Google Scholar
• Nyman SR , GoodwinK, KwasnickaD, CallawayA. Increasing walking among older people: a test of behaviour change techniques using factorial randomised N-of-1 trials. Psychol. Health.31, 313–330 (2016).
   PubMed Web of Science ®Google Scholar
• Fedele DJ , JonesJA, VolicerL, HerzLR, OppenheimFG. Effects of medication on parotid salivary flow rates in an individual with dementia of the Alzheimer type. Spec. Care Dentist.13, 215–218 (1993).
   PubMedGoogle Scholar
• Molloy DW , GuyattGH, WilsonDB, DukeR, ReesL, SingerJ. Effect of tetrahydroaminoacridine on cognition, function and behaviour in Alzheimer's disease. CMAJ144, 29–34 (1991).
   PubMed Web of Science ®Google Scholar
• Bredesen DE . Reversal of cognitive decline: a novel therapeutic program. Aging6, 707–717 (2014).
   PubMedGoogle Scholar
• Bredesen DE , AmosEC, CanickJet al. Reversal of cognitive decline in Alzheimer's disease. Aging8, 1250–1258 (2016).
   PubMedGoogle Scholar
• Galvin JE . Prevention of Alzheimer's disease: lessons learned and applied. J. Am. Geriatr. Soc65, 2128–2133 (2017).
   PubMed Web of Science ®Google Scholar
• Morris JC . The clinical dementia rating (CDR): current version and scoring rules. Neurology43, 2412–2414 (1993).
   PubMed Web of Science ®Google Scholar
• Galvin JE . The quick dementia rating system (QDRS): a rapid dementia staging tool. Alzheimers Dement.1, 249–259 (2015).
   Google Scholar
• Reitz C . Toward precision medicine in Alzheimer's disease. Ann. Transl. Med.4, 107 (2016).
   PubMed Web of Science ®Google Scholar
• Cummings J , AisenPS, DuBoisBet al. Drug development in Alzheimer's disease: the path to 2025. Alzheimers Res. Ther.8, 39 (2016).
   PubMed Web of Science ®Google Scholar